Contact

COVID-19, Why SARS-CoV-2 Pseudotyped virus?

The outbreak of COVID-19, caused by SARS-CoV-2 (2019-nCoV), has been a global public health threat and caught the worldwide concern. Due to its high pathogenicity and infectivity1, live SARS-CoV-2 should be handled under biosafety level 3 (BSL-3) conditions. GeneMedi has developed SARS-CoV-2 pseudovirus production system, from which the SARS-CoV-2 pseudotyped virus can be handled in biosafety level 2 (BSL-2)2.



GeneMedi offers:


1. SARS-CoV-2 Pseudotyped virus packaging and production (Cat.GM-2019nCoV-PSV01)

Delivery impact due to the Coronavirus Outbreak With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalot Number Size
(T,Test, formalized in 96 well, one test per well)
Price(In USD) Qty (Quantity) Sum(In USD)
GM-2019nCoV-PSV01-1 100T 7680
GM-2019nCoV-PSV01-1 200T 10880
GM-2019nCoV-PSV01-2 1000T 43520
GM-2019nCoV-PSV01-2 5000T 174080
For larger scale Click for inquiry. Click for inquiry.
Shipping Cost: 760.00
Total:

2. Effector cells: human ACE2 overexpression stable HEK293T cell lines, Catalot Number: GM-SC-293T-hACE2-01

3. SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay Service for evaluating:
1) Neutralizing antibodies
2) Peptides blockers(peptide inhibitors)
3) Types of Vaccines3(by testing immunized serum from mouse, NHP etc.)
4) Compounds targeting Spike induced cell-fusion.


SARS-CoV-2 Pseudotyped virus


GeneMedi’s SARS-CoV-2 Pseudovirus-Luciferase (Cat.GM-2019nCoV-PSV01) is recombinant pseudotyped lentiviral particles containing SARS-CoV-2 spike protein to mimic SARS-CoV-2 (2019nCoV) cell infection and cell entry4.

The SARS-CoV-2 pseudovirus particles encode firefly luciferase and RFP in their lentiviral vector genome. The firefly luciferase and RFP gene will be strongly expressed after the SARS-CoV-2 pseudovirus entry into ACE2-expressing cells. Actually, 293T-hACE2(human ACE2 overexpression stable HEK293T cell lines) is normally used as effector cell.

GM-2019nCoV-PSV01 is a powerful tool for SARS-CoV-2 related vaccine efficacy evaluation, neutralizing antibodies, peptides blockers competitors neutralization assay, and tissue-specific infection determination.


GeneMedi SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry

pdf downloadData Post Download

Picture loading failed.


Picture loading failed.

Picture loading failed.

Figure. GeneMedi-SARS-CoV-2 Pseudovirus (PSV) Based Cell Entry validation with fluorescence(A), Luciferase activity (B) and FACS (C) after 72 hours of HEK293T infection. hACE2 significantly enhanced the infection efficiency of the SARS-CoV-2 PSV.

GeneMedi SARS-CoV-2 PSV-Luciferase (Cat.GM-2019nCoV-PSV01) is recombinant pseudotyped lentiviral particles containing SARS-CoV-2 spike protein to mimic SARS-CoV-2 (2019nCoV) cell infection.

GM-2019nCoV-PSV01 is a powerful tool for SARS-CoV-2 related vaccine efficacy evaluation, neutralizing antibodies, peptides blockers competitors neutralization assay, and tissue-specific infection determination.



SARS-CoV-2(2019nCoV) Pseudotyped Virus Based Neutralization Assay


In the Pseudovirus Based Neutralization Assay (PBNA), the inhibition of viral entry into cells by neutralizing antibodies is correlated to the decreased levels of firefly luciferase signals in the ACE2 expression cells (hACE2-HEK293T).
1) Neutralizing antibodies
2) Peptides blockers (peptide inhibitors)
3) Types of Vaccines3
4) Compounds targeting Spike induced cell-fusion.


References

1 XiaolongCai. An Insight of comparison between COVID-19 (2019-nCoV) and SARS-CoV in pathology and pathogenesis. Preprint, doi:10.31219/osf.io/hw34x (2020, paper of GeneMedi).

2 Jean K. Millet1, Tiffany Tang3, Lakshmi Nathan3, Javier A. Jaimes4, Hung-Lun Hsu3,5, & Susan Daniel3, G. R. W. Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting. J Vis Exp, doi:10.3791/59010 (2019).

3 HuajunBai, X., XiaolongCai. Vaccines And Advanced Vaccines: -A landscape for advanced vaccine technology against infectious disease, COVID-19 and tumor. Preprint, doi:10.31219/osf.io/ypgx4 (2020, paper of GeneMedi).

4 Nie, J. et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect 9, 680-686, doi:10.1080/22221751.2020.1743767 (2020).




GENEMEDI
2nd Floor, Building 21, No 518, Xinzhuan Road, Shanghai, China
Email: [email protected] [email protected]
Telephone: +86-21-50478399   Fax: 86-21-50478399
Privacy Policy
Chinese Website

Ask for Protocol

Apply for Protocol and guideline

×